<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Associations between type 2 diabetic patients and a higher risk of developing <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> have been reported worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, a protective effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> has been described </plain></SENT>
<SENT sid="2" pm="."><plain>AIM: To examine in the Belgian primary care population the relation between presence of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> with and without <z:chebi fb="0" ids="6801">metformin</z:chebi> treatment and the occurrence of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN OF STUDY: Retrospective cohort study, based on the Intego database, an ongoing Belgian general practice-based morbidity registry, covering 90 general practitioners and including about 1.5 million patient-years between 1994 and 2008 </plain></SENT>
<SENT sid="4" pm="."><plain>METHOD: Cox proportional hazard analysis comparing emergence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in patients with and without type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and among patients with <z:mp ids='MP_0002055'>diabetes</z:mp> comparing emergence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in those treated with various <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drugs </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">Malignancies</z:e> occurred more in type 2 diabetic patients compared to non-diabetic controls (HR=1.84; 95% CI=1.51-2.24), adjusted for age, gender and weight </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment with both <z:chebi fb="0" ids="6801">metformin</z:chebi> and 'other' <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents was related to decreased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk (HR=0.24 and 0.22) compared to diet only in men but not in women </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: In this Belgian primary care setting, diabetic patients have higher <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> prevalences than non-diabetic patients </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, in diabetic men, not only <z:chebi fb="0" ids="6801">metformin</z:chebi> but also other <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents were associated with lower <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risks </plain></SENT>
</text></document>